Saturn V Capital Management as of June 30, 2026
Portfolio Holdings for Saturn V Capital Management
Saturn V Capital Management holds 23 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals (AMLX) | 11.9 | $83M | 4.6M | 17.96 | |
| Alumis (ALMS) | 11.8 | $82M | 2.9M | 28.14 | |
| Abivax Sa Sponsored Ads (ABVX) | 9.9 | $69M | 519k | 133.26 | |
| Vaxcyte (PCVX) | 7.1 | $50M | 853k | 58.13 | |
| Immix Biopharma (IMMX) | 6.9 | $48M | 4.7M | 10.31 | |
| Pharvaris N V (PHVS) | 6.5 | $45M | 1.3M | 34.58 | |
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 5.6 | $39M | 161k | 240.97 | |
| Celcuity (CELC) | 5.6 | $39M | 370k | 104.62 | |
| Disc Medicine (IRON) | 5.5 | $38M | 525k | 73.14 | |
| Candel Therapeutics (CADL) | 4.9 | $34M | 3.3M | 10.30 | |
| X4 Pharmaceuticals Com New (XFOR) | 4.7 | $33M | 7.0M | 4.67 | |
| Monopar Therapeutics Com New (MNPR) | 4.1 | $29M | 312k | 92.59 | |
| Dyne Therapeutics (DYN) | 3.4 | $24M | 1.1M | 22.21 | |
| Trevi Therapeutics (TRVI) | 2.8 | $20M | 1.1M | 18.65 | |
| Zura Bio Class A Ord Shs (ZURA) | 1.8 | $12M | 2.1M | 5.90 | |
| Sagimet Biosciences Com Ser A (SGMT) | 1.6 | $11M | 1.5M | 7.73 | |
| Oculis Holding Ordinary Shares (OCS) | 1.4 | $9.5M | 685k | 13.87 | |
| Inhibikase Therapeutics Com New (IKT) | 1.1 | $7.9M | 3.9M | 2.03 | |
| Vir Biotechnology (VIR) | 1.1 | $7.9M | 771k | 10.19 | |
| Adagio Therapeutics (IVVD) | 1.0 | $7.3M | 8.4M | 0.87 | |
| Alto Neuroscience Com Shs (ANRO) | 0.7 | $4.8M | 183k | 26.39 | |
| Satellos Bioscience (MSLE) | 0.4 | $2.7M | 350k | 7.78 | |
| Ovid Therapeutics (OVID) | 0.3 | $1.8M | 663k | 2.69 |
